Simulations Plus, Inc. SLP R2K
Company Overview
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
Why Investors Should Care
Revenue has grown at a 100.4% CAGR over the past five years.
Operating margin of 23.2% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.38.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Aug 2025 Revenue of $79.18M (+13.1% YoY); net profit $-64.72M.
- Trailing 12 Months Year-on-year growth — revenue +8.3%, earnings +46.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 100.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 100.35% |
| 1 Year: | 8.30% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 46.70% |
Stock Price Performance
| 1 Year: | +4.29% |
| 6 Months: | -7.04% |
| 3 Months: | +40.69% |
| 1 Month: | +10.49% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross10d ago
- RSI (14)63.24 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 100.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SLP Simulations Plus, Inc. R2K | 18.22 | -5.84 | $368.14M | 0.00% | -56.49% | -38.84% | 100.35% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Feb 2015 | May 2015 | Nov 2015 | Feb 2016 | May 2016 | Aug 2016 | Nov 2016 | Feb 2017 | May 2017 | Aug 2017 | Nov 2017 | Feb 2018 | May 2018 | Aug 2018 | Nov 2018 | Feb 2019 | May 2019 | Aug 2019 | Nov 2019 | Feb 2020 | May 2020 | Aug 2020 | Nov 2020 | Feb 2021 | May 2021 | Aug 2021 | Nov 2021 | Feb 2022 | May 2022 | Nov 2022 | Feb 2023 | May 2023 | Nov 2023 | Feb 2024 | May 2024 | Nov 2024 | Feb 2025 | May 2025 | Nov 2025 | Feb 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.47M | 9.94M | - | - | 10.35M | 12.30M | - | - | - | - | - | - | - | - | - | - | 16.23M | 14.50M | 18.30M | 18.54M | 18.92M | 22.43M | 20.36M | 18.42M | 24.29M |
| Gross Profit | 3.44M | 4.81M | 3.75M | 3.90M | 4.82M | 2.90M | 4.08M | 4.15M | 5.30M | 4.29M | 5.33M | 5.24M | 6.53M | 4.57M | 5.34M | 6.26M | 7.61M | 5.74M | 6.76M | 7.68M | 9.63M | 6.87M | 8.27M | 10.24M | 10.31M | 7.06M | 9.66M | 11.97M | 12.40M | 9.29M | 13.13M | 13.27M | 9.85M | 13.22M | 13.26M | 10.22M | 13.13M | 13.03M | 10.89M | 16.14M |
| Operating Income | 1.48M | 2.85M | 1.73M | 1.72M | 2.79M | - | 1.93M | 1.79M | 3.10M | - | 2.56M | 2.42M | 3.42M | - | 2.09M | 2.73M | 3.88M | - | 2.72M | 2.83M | 3.86M | - | 3.05M | 3.49M | 4.54M | - | 3.79M | 5.48M | 4.95M | 878.00K | 4.03M | 4.10M | 960.00K | 4.44M | 1.88M | 126.00K | 2.71M | -74.23M | 713.00K | 5.63M |
| Net Income | 970.23K | 1.85M | 1.11M | 1.15M | 1.91M | 789.00K | 1.36M | 1.20M | 2.08M | 1.15M | 1.72M | 3.48M | 2.41M | 1.34M | 1.54M | 2.10M | 2.89M | 2.06M | 2.06M | 2.15M | 2.94M | 2.19M | 2.48M | 3.21M | 3.79M | 305.00K | 3.03M | 4.41M | 4.09M | 1.25M | 4.17M | 4.01M | 1.95M | 4.03M | 3.14M | 206.00K | 3.07M | -67.32M | 676.00K | 4.54M |
| Diluted EPS | 0.06 | 0.11 | 0.06 | 0.07 | 0.11 | 0.06 | 0.08 | 0.07 | 0.12 | 0.06 | 0.10 | 0.19 | 0.13 | 0.07 | 0.09 | 0.12 | 0.16 | 0.11 | 0.11 | 0.12 | 0.16 | 0.11 | 0.12 | 0.15 | 0.18 | 0.01 | 0.15 | 0.21 | 0.20 | 0.06 | 0.20 | 0.20 | 0.10 | 0.20 | 0.15 | 0.01 | 0.15 | -3.35 | 0.03 | 0.22 |
| R&D Expense | 360.71K | 348.29K | 351.31K | 461.39K | 348.43K | - | 290.30K | 408.54K | 253.80K | - | 360.82K | 484.33K | 508.36K | - | 529.64K | 724.03K | 643.25K | - | 526.00K | 748.00K | 752.00K | - | 809.00K | 1.29M | 670.00K | - | 882.00K | 902.00K | 655.00K | 1.17M | 1.32M | 945.00K | 1.22M | 1.31M | 1.30M | 1.85M | 2.14M | 1.22M | 2.98M | 3.47M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Aug 2012 | Aug 2013 | Aug 2014 | Aug 2015 | Aug 2016 | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Aug 2022 | Aug 2023 | Aug 2024 | Aug 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.45K | 10.07M | 11.46M | 18.31M | 19.97M | 24.14M | 29.67M | 33.97M | 41.59M | 46.47M | 53.91M | 59.58M | 70.01M | 79.18M |
| Gross Profit | 7.94M | 8.42M | 9.83M | 13.92M | 15.37M | 17.83M | 21.67M | 24.94M | 30.94M | 35.87M | 43.08M | 47.95M | 43.15M | 46.22M |
| Operating Income | 3.61M | 4.07M | 4.44M | 5.86M | 7.23M | 8.26M | 10.30M | 10.65M | 11.61M | 11.25M | 14.91M | 8.72M | 6.13M | -70.73M |
| Net Income | 3.03M | 2.89M | 3.03M | 3.84M | 4.95M | 5.79M | 8.93M | 8.58M | 9.33M | 9.78M | 12.48M | 9.96M | 9.95M | -64.72M |
| Diluted EPS | 0.19 | 0.18 | 0.18 | 0.23 | 0.29 | 0.33 | 0.50 | 0.48 | 0.50 | 0.47 | 0.60 | 0.49 | 0.49 | -3.22 |
| R&D Expense | 947.56K | 802.37K | 952.77K | 1.33M | 1.45M | 1.37M | 1.79M | 2.50M | 2.98M | 4.05M | 3.21M | 4.50M | 5.75M | 6.88M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Aug 2011 | Aug 2012 | Aug 2013 | Aug 2014 | Aug 2015 | Aug 2016 | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Aug 2022 | Aug 2023 | Aug 2024 | Aug 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 17.35M | 16.06M | 20.98M | 27.34M | 27.81M | 38.51M | 43.28M | 45.20M | 168.42M | 179.98M | 188.38M | 186.10M | 196.64M | 131.94M |
| Total Equity | 14.04M | 15.14M | 14.24M | 15.44M | 19.53M | 22.73M | 25.80M | 31.92M | 37.68M | 156.03M | 165.78M | 178.25M | 170.03M | 182.43M | 124.80M |
| Cash & Equivalents | 10.18M | 12.70M | 10.18M | 8.61M | 8.55M | 8.03M | 6.22M | 9.40M | 11.43M | 49.21M | 36.98M | 51.57M | 57.52M | 10.31M | 30.85M |
| Long Term Debt | - | - | - | - | - | - | 5.74M | 3.33M | - | - | - | - | - | - | - |
| Total Liabilities | - | 2.20M | 1.82M | 5.55M | 7.81M | 5.08M | 12.71M | 11.36M | 7.52M | 12.39M | 14.20M | 10.13M | 16.07M | 14.21M | 7.13M |
| Current Liabilities | - | 1.42M | 626.31K | 1.39M | 3.61M | 2.13M | 2.04M | 4.83M | 4.78M | 5.51M | 11.57M | 7.74M | 11.99M | 12.07M | 6.72M |
Cash Flows (Annual)
Figures in USD.
| Metric | Aug 2012 | Aug 2013 | Aug 2014 | Aug 2015 | Aug 2016 | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Aug 2022 | Aug 2023 | Aug 2024 | Aug 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 3.78M | 2.56M | - | 7.14M | 5.42M | 6.88M | 9.29M | 11.64M | 10.91M | 19.20M | 17.90M | 21.86M | 13.32M | 18.13M |
| Investing Cash Flow | 839.49K | -1.18M | - | -3.13M | -1.95M | -4.36M | -2.33M | -1.96M | -75.50M | -26.74M | 4.30M | 7.37M | -53.97M | 3.56M |
| Financing Cash Flow | - | - | - | -4.07M | -3.98M | -4.34M | -3.77M | -7.65M | 102.37M | -4.68M | -7.62M | -23.27M | -6.57M | -1.15M |
| Capital Expenditure | -106.83K | -53.15K | -24.49K | -71.37K | -39.12K | -175.96K | -183.29K | -138.00K | -231.00K | -1.63M | -819.00K | -453.00K | -566.00K | -713.00K |
| Free Cash Flow | 3.68M | 2.51M | - | 7.06M | 5.38M | 6.70M | 9.10M | 11.50M | 10.68M | 17.58M | 17.08M | 21.40M | 12.75M | 17.41M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | 0 | 0 | 20.00M | 0 | 0 |
| Dividends Paid | 2.38M | 4.00M | 3.08M | 3.38M | 3.41M | 3.45M | 4.16M | 4.20M | 4.25M | 4.81M | 4.85M | 4.81M | 4.80M | 0 |
Ratios (Annual)
Figures in %.
| Metric | Aug 2012 | Aug 2013 | Aug 2014 | Aug 2015 | Aug 2016 | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Aug 2022 | Aug 2023 | Aug 2024 | Aug 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 84,013.8% | 83.6% | 85.8% | 76.0% | 77.0% | 73.9% | 73.1% | 73.4% | 74.4% | 77.2% | 79.9% | 80.5% | 61.6% | 58.4% |
| Operating Margin % | 38,225.1% | 40.4% | 38.7% | 32.0% | 36.2% | 34.2% | 34.7% | 31.3% | 27.9% | 24.2% | 27.7% | 14.6% | 8.8% | -89.3% |
| Net Margin % | 32,044.5% | 28.7% | 26.4% | 21.0% | 24.8% | 24.0% | 30.1% | 25.3% | 22.4% | 21.1% | 23.2% | 16.7% | 14.2% | -81.7% |
| ROE % | 20.0% | 20.3% | 19.6% | 19.7% | 21.8% | 22.4% | 28.0% | 22.8% | 6.0% | 5.9% | 7.0% | 5.9% | 5.5% | -51.9% |
| ROCE % | 22.7% | 26.4% | 22.7% | 24.7% | 28.2% | 22.7% | 26.8% | 26.3% | 7.1% | 6.7% | 8.3% | 5.0% | 3.3% | -56.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | First Light Asset Management, LLC | 13.03% | 2.63M | $48.31M |
| 2 | Blackrock Inc. | 6.20% | 1.25M | $22.98M |
| 3 | Morgan Stanley | 4.39% | 887.51K | $16.29M |
| 4 | First Eagle Investment Management, LLC | 3.67% | 742.07K | $13.62M |
| 5 | Vanguard Capital Management LLC | 3.66% | 739.72K | $13.57M |
| 6 | Marshall Wace LLP | 3.13% | 632.69K | $11.61M |
| 7 | Rockefeller Capital Management L.P. | 2.91% | 587.64K | $10.78M |
| 8 | Tributary Capital Management, LLC | 2.71% | 548.42K | $10.06M |
| 9 | Meros Investment Management, Lp | 2.47% | 500.02K | $9.18M |
| 10 | Royce & Associates LP | 2.12% | 427.42K | $7.84M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SLP
Sylvania Platinum (AIM:SLP) Stock Sees Modest Fair Value Lift As Analysts Weigh Cash Generation - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPQi1xLV9xVzZvYUZyQWNNSjVKS3BlUzFRRVZqTVlDZTEtbGRTdFBLZ0FFb0Zvb0tqYkZ4SEZ6N3poVENwbVJ5N3J6TTROQkdZVUd0Tmo2THZpdmR0QWpaekNSaUQ4QTRfN2IwTS00ZUQzSWUzWHU2blh5cjRXQ2dnRTJTalBVdG5EbVc4T3…
Simulations Plus (NASDAQ:SLP) Beats Q3 Estimates by Wide Margin but Shares Edge Lower on Profit-Taking - ChartMill
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxOdm9uTTRCOEFPZVIwWmNSQzE1bDdGS1IxTVFpdTNPLUUwRWxaODJQZnFCeXpnV0t5M0pJQmFFZ3V0MGRidVdlcm1mRUhsR1I3Um96N3A3UTJKNVlFMENkVElKNkg3UHpPYUlOem1qdjBYOWV6bW5rckc4cWlpZTBISC1NOXF3bkZFOWFZZW…
SIMULATIONS PLUS ($SLP) Releases Q3 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNcUh5cDNKeEtOQ0Fpa3JDczlOVjVvODZfa2laRWRQZzFDM0VoR1VoR3ZxX3BRdjNCcjVOM0tnMldiRjAya2RkSXF6UENraThUcUhRZjNTWE9TaDFzVFdoRUJMV3Y4WmRCdUNPTjFMcHZ6QjZFUjczVmxRSzJpZmZsemJFaUlwZ0FQcVMwcH…
Simulations Plus posts $21.9M quarter as Altaris buyout nears - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQb1Y2Zk9FSG5mcjloc2NSeFUzYkMtYlJmVWQ1UUZlUXM5Xy1tM3ZJM3FBbHZWSjB2N3M0dWwtMTI4bFdXN2JLTzhoTkpJWExkdEdHeDVEYjZBZFNPdk5KR09sQmRMc0dvZVBiQ3J2RzdhRkk5cmdId3FwWk9iSnZ6QmN3cndhVHVWV2d4UX…
Simulations Plus, Inc. (NASDAQ:SLP) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPTEFoelVueVhPTTU5LTNuMzR6azRtbm40cEE5UTdxWEhJMHBjZ1dVeW5sc3dzeDBpZVI5TGxDLTlPS0RUNjl3dDN0bXhzczc3LWZfZ2tHWHJDcXNPcmUyQzI4UnluNUxvelp5OUE5OGt0N1o5NDJvR0pDeHZ2M2pwMFNlakFnTW82MU1HcW…
Precision Trading with Simulations Plus Inc. (SLP) Risk Zones - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxOb051bjd2N1NwV3hEbS1sSl9XUEFFQ3lIMU90b0RoM0hzdzh5ZWRMQmZJTHJWMWxuZFAwMzB2NW93ODNiLUFKOTFCcTFlM1l1QkRMOVRuR2NvTW14MUZ4MTRxNWRwbThtNlZoVnp4THc2WmtrRE56Uzg1X3ZoeFNaelIwUHdIUkRLZHdwVz…
SLP — Frequently Asked Questions
What is the current share price of Simulations Plus, Inc. (SLP)?
As of 2026-07-14 21:23 PDT, Simulations Plus, Inc. (SLP) trades at $18.22 on NasdaqGS. Its 52-week range is $11.36 to $20.84.
What is the market capitalisation of SLP?
Simulations Plus, Inc. (SLP) has a market capitalisation of $368.14M on NasdaqGS.
What is the P/E ratio of SLP?
SLP trades at a trailing price-to-earnings (P/E) ratio of -5.84. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.46.
What is the return on equity (ROE) of SLP?
SLP has a return on equity (ROE) of -38.84%. Its return on capital employed (ROCE) is -56.49%.
Is SLP a good stock to buy?
This page provides a data-driven analysis of Simulations Plus, Inc. (SLP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.